Taken together, these results show that although both CpG and NP-CpG delivered in a therapeutic setting to allergic mice could reduce allergy markers (IgE, eosinophilia), NP-CpG was significantly more potent than free CpG overall at reducing Th2 immunity. Here, IGHE is linked to allergic disease.